Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status
Alexander Hein, Andreas D. Hartkopf, Julius Emons, Michael P. Lux, Bernhard Volz, Florin‐Andrei Taran, Friedrich Overkamp, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Lena A. Wurmthaler, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Christian M. Kurbacher, Rachel Wuerstlein, Christoph Thomssen, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja Fehm, D. Wallwiener, Sara Y. Brucker, Andreas Schneeweiß, Hans‐Christian Kolberg
Topics & Concepts
MedicineImmunohistochemistryInternal medicineHazard ratioOncologyConfidence intervalBreast cancerClinical trialCancerPopulationProportional hazards modelEnvironmental healthHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesAdvanced Breast Cancer Therapies